Cargando…
METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway
BACKGROUND: Cisplatin resistance is a big challenge for ovarian cancer (OC) therapy. The abnormal expression of long noncoding RNAs (lncRNAs) regulated by N6‐methyladenosine (m6A) modification has been confirmed to play the crucial roles in OC. The aim of this study is to explore the regulatory mech...
Autor principal: | Cui, Shoubin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756993/ https://www.ncbi.nlm.nih.gov/pubmed/36336887 http://dx.doi.org/10.1002/jcla.24761 |
Ejemplares similares
-
RHPN1-AS1 promotes ovarian carcinogenesis by sponging miR-485-5p and releasing TPX2 mRNA
por: Cui, Shoubin, et al.
Publicado: (2021) -
RHPN1-AS1 promotes ovarian carcinogenesis by sponging miR-6884-5p thus releasing TOP2A mRNA
por: Cui, Shoubin, et al.
Publicado: (2021) -
Prognostic potential of lncRNA RHPN1-AS1 in glioma
por: Wu, Yong, et al.
Publicado: (2020) -
METTL3-Mediated m(6)A Modification of lncRNA MALAT1
Facilitates Prostate Cancer Growth by Activation of PI3K/AKT
Signaling
por: Mao, Yuanshen, et al.
Publicado: (2022) -
LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma
por: Song, Xue-zhen, et al.
Publicado: (2020)